drug · oligonucleotide
patient view →golodirsen
Marketedupdated 2mo agoby $SRPT Sarepta Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for duchenne muscular dystrophy and muscular dystrophy.
indications
investigational
Duchenne Muscular Dystrophy
targets
Dystrophin pre-mRNA
all catalysts(1)
filing · 1
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that